Researchers identified three age-related proteins that may play key roles in PH progression as possible treatment targets.

A lack of the protein beta-arrestin 1 reduces the ability of pulmonary arteries to widen, leading to pulmonary hypertension, a study found.

Hypertension in the lungs is a relatively rare but very serious disease that is usually fatal within two years if left untreated. Current therapies can slow down its progression, but no cure exists.

BACKGROUND: BCR-ABL tyrosine kinase inhibitors (TKIs) have been increasingly linked to pulmonary arterial hypertension (PAH) since 2009, although supporting evidence is limited. Our objective was to ...

PHocus enrollment completed in under 12 months from first patient dosed, representing a rapid enrollment pace in pulmonary hypertension ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Pulmonary hypertension in and of itself is ...

Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease: Gothenburg, Sweden Thursday, February 5, 2026, 14:00 Hr ...

Sotatercept, an activin-signaling inhibitor, reduces morbidity and mortality among patients with long-standing pulmonary arterial hypertension. Its effects in patients with pulmonary arterial ...

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that go from your heart to your lungs. It happens when these arteries become narrow or blocked, making it harder ...

Novel combinations and targeted pathway inhibitors may improve adherence and blood pressure control in patients with ...

Hypertension in the lungs is a relatively rare but very serious disease that is usually fatal within two years if left ...